

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10A




Figure 10B




Figure 11




Figure 12




Figure 13




Figure 14

		TriTAC 75	TriTAC 74
Affinity measurements (M)	Kd hu tumor target	5.9E-10	6.0E-10
	Kd cy tumor target	3.2E-09	
	Kd huCD3E	1.0E-08	5.2E-08
	Kd huALB	5.9E-09	6.5E-09
Binding in 50% Cyno Serum (M): measured by MSD (ELISA-like) assay	no serum	1.4E-08	2.1E-08
	50% cyno serum	5.3E-09	3.0E-08
Cyno Serum Stability / HSA Shift (M): measured using SKOV3 TDCC	untreated	2.3E-12	2.0E-11
	untreated + huALB	1.3E-11	9.5E-11
	Pre-treated 2 days 37 cyno serum	2.1E-12	6.8E-12
Serum stability and activity in cyno serum (M): measured by OVCAR TDCC, assay run +/- 20% cyno serum	untreated	1.4E-12	1.6E-12
	untreated, assay with cyno serum	4.1E-12	3.2E-11
	Pre-treated 2 days 37 cyno serum, assay with cyno serum	2.7E-12	1.9E-11

Figure 15

